v3.7.0.1

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
Statements of Operations (Unaudited) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Revenue
Operating expenses
Research and Development-Net of Contracts	(1,150)	40,404	75,392	55,119
General and administrative	76,839	62,259	102,308	72,195
Loss from Operations	(75,689)	(102,663)	(177,700)	(127,314)
Other Income (Expense)
Interest Expense-related party	(212)		(580)
Interest Expense accrued-convertible notes	(2,248)		(4,472)
Interest Income-related party		132		277
Interest Income-other	5	10	60	110
Net Loss before provision for taxes	(78,144)	(102,521)	(182,692)	(126,927)
Income tax provision
Net loss	$ (78,144)	$ (102,521)	$ (182,692)	$ (126,927)
Basic and diluted Loss per common share (in dollars per share)	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
Weighted average common shares outstanding (in shares)	45,000,000	45,000,000	45,000,000	45,000,000

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

No definition available.

Shuttle Pharmaceuticals, Inc. 10-Q